Castle Biosciences and Skin Cancer Survivor Teddi Mellencamp Arroyave Launch Campaign to Increase Awareness of Melanoma
Castle Biosciences (Nasdaq: CSTL) has partnered with Teddi Mellencamp Arroyave, a stage II melanoma survivor, to launch a campaign raising awareness about melanoma prevention, detection, and management. Mellencamp Arroyave will share her personal journey with melanoma on Instagram, alongside discussions with Dr. Aaron S. Farberg and melanoma survivor Morgan England.
The campaign aims to educate the public about melanoma, the deadliest form of skin cancer, which claims nearly 20 American lives daily. Castle's DecisionDx®-Melanoma test provides personalized information about a patient's risk of melanoma recurrence, metastasis, and sentinel lymph node positivity, helping guide treatment decisions and improve patient survival.
Castle Biosciences (Nasdaq: CSTL) ha collaborato con Teddi Mellencamp Arroyave, una sopravvissuta al melanoma di stadio II, per lanciare una campagna che sensibilizzi sul prevenzione, rilevazione e gestione del melanoma. Mellencamp Arroyave condividerà il suo percorso personale con il melanoma su Instagram, insieme a discussioni con il Dr. Aaron S. Farberg e la sopravvissuta al melanoma Morgan England.
La campagna mira a educare il pubblico sul melanoma, la forma più letale di cancro della pelle, che provoca quasi 20 vittime al giorno negli Stati Uniti. Il test DecisionDx®-Melanoma di Castle fornisce informazioni personalizzate sul rischio di recidiva del melanoma, metastasi e positività del linfonodo sentinella, aiutando a guidare le decisioni terapeutiche e migliorando la sopravvivenza dei pazienti.
Castle Biosciences (Nasdaq: CSTL) se ha asociado con Teddi Mellencamp Arroyave, una sobreviviente de melanoma en estadio II, para lanzar una campaña que crea conciencia sobre prevención, detección y manejo del melanoma. Mellencamp Arroyave compartirá su viaje personal con el melanoma en Instagram, junto a discusiones con el Dr. Aaron S. Farberg y la sobreviviente de melanoma Morgan England.
La campaña tiene como objetivo educar al público sobre el melanoma, la forma más mortal de cáncer de piel, que cobra casi 20 vidas americanas diariamente. La prueba DecisionDx®-Melanoma de Castle proporciona información personalizada sobre el riesgo de recurrencia del melanoma, metástasis y positividad de los ganglios linfáticos centinelas, ayudando a guiar las decisiones de tratamiento y mejorar la supervivencia del paciente.
캐슬 바이오사이언스(Castle Biosciences, Nasdaq: CSTL)는 II기 흑색종 생존자인 Teddi Mellencamp Arroyave와 협력하여 흑색종 예방, 조기 발견 및 관리에 대한 인식을 높이는 캠페인을 시작했습니다. Mellencamp Arroyave는 인스타그램에서 흑색종과 관련된 자신의 개인적인 여정을 공유할 것이며, Aaron S. Farberg 박사 및 흑색종 생존자인 Morgan England와의 논의도 포함됩니다.
이번 캠페인은 가장 치명적인 피부암인 흑색종에 대해 대중을 교육하는 것을 목표로 하며, 흑색종은 매일 거의 20명의 미국인의 생명을 앗아가고 있습니다. 캐슬의 DecisionDx®-Melanoma 검사는 환자의 흑색종 재발, 전이 및 감시 림프절 양성 여부에 대한 개인화된 정보를 제공하여 치료 결정에 도움을 주고 환자의 생존율을 개선하는 데 기여합니다.
Castle Biosciences (Nasdaq: CSTL) s'est associé à Teddi Mellencamp Arroyave, une survivante d'un mélanome de stade II, pour lancer une campagne de sensibilisation sur la prévention, la détection et la gestion du mélanome. Mellencamp Arroyave partagera son parcours personnel avec le mélanome sur Instagram, avec des discussions avec le Dr Aaron S. Farberg et la survivante du mélanome Morgan England.
La campagne vise à éduquer le public sur le mélanome, la forme la plus mortelle de cancer de la peau, qui emporte chaque jour près de 20 vies américaines. Le test DecisionDx®-Melanoma de Castle fournit des informations personnalisées sur le risque de récidive du mélanome, de métastases et de positivité des ganglions lymphatiques sentinelles, aidant ainsi à guider les décisions de traitement et à améliorer la survie des patients.
Castle Biosciences (Nasdaq: CSTL) hat sich mit Teddi Mellencamp Arroyave, einer Überlebenden des Melanoms im Stadium II, zusammengetan, um eine Kampagne zur Sensibilisierung für Prävention, Erkennung und Behandlung von Melanomen zu starten. Mellencamp Arroyave wird ihre persönliche Reise mit dem Melanom auf Instagram teilen, zusammen mit Diskussionen mit Dr. Aaron S. Farberg und der Melanomüberlebenden Morgan England.
Die Kampagne zielt darauf ab, die Öffentlichkeit über Melanom, die tödlichste Form von Hautkrebs, aufzuklären, die täglich fast 20 amerikanische Leben fordert. Der DecisionDx®-Melanoma-Test von Castle bietet personalisierte Informationen über das Risiko eines Melanomrezidivs, Metastasierung und die Positivität von Sentinel-Lymphknoten, um die Behandlungsentscheidungen zu lenken und die Überlebensrate der Patienten zu verbessern.
- Partnership with a well-known personality (Teddi Mellencamp Arroyave) for melanoma awareness campaign
- Potential increase in visibility and adoption of DecisionDx®-Melanoma test
- DecisionDx®-Melanoma test shown to improve patient survival
- None.
Campaign will focus on empowering patients impacted by melanoma
“When I first learned that the weird spot on my back was melanoma, I was truly in shock,” said Mellencamp Arroyave. “Yes, I tanned and laid out in the sun as a teen, but as I got older, I became more aware about taking care of my skin. Skin cancer was not anything I thought would affect me or that those choices I made when I was younger would catch up with me. After melanoma was removed from my shoulder, the 14th lesion resulting in a major surgery, the gravity of my diagnosis had become evident.
“I want to share my story, both to encourage others to advocate for their personal health care and to educate anyone and everyone that this disease does not discriminate, looks different on every individual, and that taking care of your skin and keeping up with your skin checks is so important.”
Melanoma will claim nearly 20 American lives each day this year, making it the most aggressive form of skin cancer.1 Castle’s DecisionDx®-Melanoma test is designed to provide personalized information about a patient’s risk of melanoma recurrence, metastasis and sentinel lymph node positivity based on the biology of their tumor. This information can help guide important decisions regarding a patient’s treatment plan and follow-up care that have been shown to improve patient survival.2,3
Mellencamp Arroyave will be sharing more about her melanoma journey in a series of conversations on Instagram (@teddimellencamp) with Aaron S. Farberg, M.D., double board-certified dermatologist, chief medical officer of Bare Dermatology in
“I would tell others with melanoma or any cancer diagnosis that you have to be your own advocate,” commented
“Melanomas with similar tumor features can have vastly different biology, which can impact how they behave,” added Farberg. “Is the tumor more aggressive? Is it likely to return or spread? The DecisionDx-Melanoma test is designed to provide this vital information that you can’t always get from a patient’s clinical or pathologic risk factors … information that helps me make better, risk-aligned decisions with my patients on how we can treat their melanoma to help improve the outcome of their disease.”
To learn more about melanoma and Castle’s DecisionDx-Melanoma test, visit yourmelanoma.com.
About DecisionDx®-Melanoma
DecisionDx-Melanoma is a gene expression profile risk stratification test. It is designed to inform two clinical questions in the management of cutaneous melanoma: a patient’s individual risk of sentinel lymph node (SLN) positivity and a patient's personal risk of melanoma recurrence and/or metastasis. By integrating tumor biology with clinical and pathologic factors using a validated proprietary algorithm, DecisionDx-Melanoma is designed to provide a comprehensive and clinically actionable result to guide risk-aligned patient care. DecisionDx-Melanoma has been shown to be associated with improved patient survival and has been studied in more than 10,000 patient samples. DecisionDx-Melanoma’s clinical value is supported by 50 peer-reviewed and published studies, providing confidence in disease management plans that incorporate the test’s results. Through March 31, 2024, DecisionDx-Melanoma has been ordered more than 164,000 times for patients diagnosed with cutaneous melanoma.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis, psoriasis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, TissueCypher, IDgenetix, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. These forward-looking statements include, but are not limited to, statements concerning: the ability of DecisionDx-Melanoma test to (i) provide personalized information about a patient’s risk of melanoma recurrence, metastasis and sentinel lymph node positivity based on the biology of their tumor and (ii) help guide important decisions regarding a patient’s treatment and follow-up care that have been shown to improve patient survival. The words “believe,” “can,” “may” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation: subsequent study or trial results and findings may contradict earlier study or trial results and findings or may not support the results obtained in these studies, including with respect to the discussion of our tests in this press release; actual application of our tests may not provide the aforementioned benefits to patients; and the risks set forth under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law.
- American Academy of Dermatology; https://www.aad.org/media/stats-skin-cancer; accessed July 19, 2024
- Bailey CN, Martin BJ, Petkov VI, et al. 31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis: A SEER Collaboration. JCO Precis. Oncol. 2023; 7. doi: 10.1200/PO.23.00044
-
Dhillon S, Duarte-Bateman D, Fowler G, et al. Routine imaging guided by a 31-gene expression profile assay results in earlier detection of melanoma with decreased metastatic tumor burden compared to patients without surveillance imaging studies. Arch Dermatol Res. 2023. https://doi.org/10.1007/s00403-023-02613-6.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240722546824/en/
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
amarshall@castlebiosciences.com
Source: Castle Biosciences Inc.
FAQ
What is the purpose of Castle Biosciences' partnership with Teddi Mellencamp Arroyave?
What is the DecisionDx®-Melanoma test offered by Castle Biosciences (CSTL)?
How many American lives does melanoma claim daily according to the Castle Biosciences (CSTL) press release?
Who will Teddi Mellencamp Arroyave be sharing her melanoma journey with on Instagram for Castle Biosciences (CSTL)?
